

Asia Pacific Blood Glucose Monitoring Market Research Report Forecast to 2032

Market Report | 2024-10-12 | 111 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

Asia Pacific Blood Glucose Monitoring Market Research Report Information, By Product Type (Invasive Glucose Monitoring, Flash Glucose Monitoring, and CGM), By Application (Type 1 Diabetes, and Type 2 Diabetes), By End-User (Diagnostics Center, Hospitals, and Clinics), And, By Region (Asia-Pacific) -Market Forecast till 2032

Overview of the Market

In 2022, the blood glucose monitoring market in Asia Pacific was estimated to be worth USD 1.1 billion. The blood glucose monitoring market in Asia Pacific is expected to expand at a compound annual growth rate (CAGR) of 13.60% from 2023 to 2032, from USD 1.25 billion in 2023 to USD 3.46 billion. The primary factors propelling the market's growth are the increasing prevalence of diabetes and the growing need for reliable glucose monitoring devices.

The Asia Pacific Blood Glucose Monitoring Market CAGR is being driven by the increasing prevalence of diabetes in the region. Most people with diabetes reside in Asia-Pacific countries, such as China and India, where the prevalence rate is typically about 8.5%. Diabetes is effectively diagnosed and treated with blood glucose-measuring devices. The growing number of diabetics utilizing blood glucose monitoring devices is driving the market. One of the main causes of the disease condition, especially type 2 diabetes, is thought to be obesity. Furthermore, other factors, such as innovations and technological developments, facilitate the measurement of blood glucose levels. The early identification of hypoglycemic and hyperglycemic conditions, which these devices aid with, usually propels the market for glucose monitoring.

Perspectives on Market Segments

Based on product type, the Asia Pacific blood glucose monitoring market is segmented into three categories: CGM, flash glucose monitoring, and invasive glucose monitoring.

Both Type 1 and Type 2 diabetes are included in the Asia Pacific Blood Glucose Monitoring market segmentation, which is based on its application.

Diagnostic centers, hospitals, and clinics are included in the end-user-based market segmentation for blood glucose monitoring in Asia Pacific.

Local Perspectives

The report offers market insights for Asia-Pacific by region. Over the anticipated period, the China Blood Glucose Monitoring market is anticipated to hold a dominant position. Demand in the industry has been driven by a significant portion of the country's patient population. The rise of the sector has been spurred by the opportunity to spend more money on disease control and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

treatment. Increased consumer awareness, easier access to products, and company growth by industry players nationwide will all contribute to the market's growth. Additionally, the nation's aging population is expected to increase industry demand because older adults are more likely to develop type 2 diabetes. Government initiatives and campaigns to promote diabetes care will also encourage company expansion.

Key Players

Abbott Laboratories, Arkay Inc., Bayer Healthcare AG, F. Hoffmann-La Roche, Goldsite Diagnostics Inc., GlySure Ltd., Sphere Medical, Dexcom, LifeScan, and other prominent companies are part of the Asia Pacific blood glucose monitoring market.

Table of Contents:

TABLE OF CONTENTS

1EXECUTIVE SUMMARY16

2MARKET INTRODUCTION18

2.1DEFINITION18

2.2SCOPE OF THE STUDY18

2.3RESEARCH OBJECTIVE18

2.4MARKET STRUCTURE18

3RESEARCH METHODOLOGY19

3.1OVERVIEW19

3.2DATA FLOW21

3.2.1DATA MINING PROCESS21

3.3PURCHASED DATABASE:22

3.4SECONDARY SOURCES:23

3.4.1SECONDARY RESEARCH DATA FLOW:24

3.5PRIMARY RESEARCH:25

3.5.1PRIMARY RESEARCH DATA FLOW:26

3.6APPROACHES FOR MARKET SIZE ESTIMATION:27

3.6.1REVENUE ANALYSIS APPROACH27

3.7DATA FORECASTING28

3.7.1DATA FORECASTING TECHNIQUE28

3.8DATA MODELING29

3.8.1MICROECONOMIC FACTOR ANALYSIS:29

3.8.2DATA MODELING:30

3.9TEAMS AND ANALYST CONTRIBUTION32

4MARKET DYNAMICS34

4.1INTRODUCTION34

4.2DRIVERS35

4.2.1INCREASING INCIDENCES OF DIABETES ACROSS THE ASIA-PACIFIC35

4.2.2RISING AWARENESS AMONG INDIVIDUALS ABOUT THE BENEFITS OF BLOOD GLUCOSE MONITORING AND PATIENT EDUCATION35

4.2.3INCREASING GERIATRIC POPULATION36

4.3RESTRAINTS37

4.3.1HIGH COST OF BLOOD GLUCOSE MONITORING SYSTEMS37

4.4OPPORTUNITY38

4.4.1INCREASING GOVERNMENT INITIATIVES38

5MARKET FACTOR ANALYSIS39

5.1PORTER'S FIVE FORCES MODEL39

5.1.1THREAT OF NEW ENTRANTS39

5.1.2	BARGAINING POWER OF SUPPLIERS	40
5.1.3	THREAT OF SUBSTITUTES	40
5.1.4	BARGAINING POWER OF BUYERS	40
5.1.5	INTENSITY OF RIVALRY	40
5.2	IMPACT OF COVID-19 ON THE ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET	41
6	ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT	43
6.1	OVERVIEW	43
6.2	SELF-MONITORING DEVICES	45
6.2.1	BLOOD GLUCOSE METER	46
6.2.2	TESTING STRIPS	46
6.2.3	LANCETS	47
6.3	CONTINUOUS GLUCOSE MONITORING SYSTEMS	47
6.3.1	SENSORS	48
6.3.2	TRANSMITTER AND RECEIVERS	49
7	ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET, BY TESTING SITE	50
7.1	OVERVIEW	50
7.2	FINGERTIP SITE	52
7.3	ALTERNATE SITE	52
8	ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION	54
8.1	OVERVIEW	54
8.2	TYPE 2 DIABETES	56
8.3	TYPE 1 DIABETES	56
8.4	GESTATIONAL DIABETES	57
9	ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET, BY END USER	58
9.1	OVERVIEW	58
9.2	HOSPITALS & CLINICS	60
9.3	HOMECARE SETTINGS	60
10	ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY	62
10.1	OVERVIEW	62
10.1.1	AUSTRALIA	66
10.1.2	VIETNAM	67
10.1.3	MALAYSIA	69
10.1.4	INDONESIA	70
10.1.5	PHILIPPINES	72
10.1.6	THAILAND	73
11	COMPETITIVE LANDSCAPE	76
11.1	INTRODUCTION	76
11.2	MARKET SHARE ANALYSIS, 2022	76
11.3	COMPETITOR DASHBOARD	77
11.4	PUBLIC PLAYERS STOCK SUMMARY	78
11.5	COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL	78
11.6	KEY DEVELOPMENTS & GROWTH STRATEGIES	79
11.6.1	COMPANY EXPANSION	79
12	COMPANY PROFILES	80
12.1	ASCENSIA DIABETES CARE HOLDINGS AG	80
12.1.1	COMPANY OVERVIEW	80
12.1.2	FINANCIAL OVERVIEW	81

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.3	PRODUCTS OFFERED	81
12.1.4	KEY DEVELOPMENTS	81
12.1.5	SWOT ANALYSIS	82
12.1.6	KEY STRATEGIES	82
12.2	B. BRAUN SE	83
12.2.1	COMPANY OVERVIEW	83
12.2.2	FINANCIAL OVERVIEW	84
12.2.3	PRODUCTS OFFERED	84
12.2.4	KEY DEVELOPMENTS	85
12.2.5	SWOT ANALYSIS	85
12.2.6	KEY STRATEGIES	85
12.3	SINOCARE	86
12.3.1	COMPANY OVERVIEW	86
12.3.2	FINANCIAL OVERVIEW	86
12.3.3	PRODUCTS OFFERED	86
12.3.4	KEY DEVELOPMENTS	87
12.3.5	KEY STRATEGIES	87
12.4	I-SENS, INC.	88
12.4.1	COMPANY OVERVIEW	88
12.4.2	FINANCIAL OVERVIEW	89
12.4.3	PRODUCTS OFFERED	90
12.4.4	KEY DEVELOPMENTS	90
12.4.5	KEY STRATEGY	90
12.5	TERUMO CORPORATION	91
12.5.1	COMPANY OVERVIEW	91
12.5.2	FINANCIAL OVERVIEW	92
12.5.3	PRODUCTS OFFERED	93
12.5.4	KEY DEVELOPMENTS	93
12.5.5	KEY STRATEGY	93
12.6	DEXCOM, INC	94
12.6.1	COMPANY OVERVIEW	94
12.6.2	FINANCIAL OVERVIEW	95
12.6.3	PRODUCTS OFFERED	96
12.6.4	KEY DEVELOPMENTS	96
12.6.5	KEY STRATEGIES	96
12.7	MEDTRONIC	97
12.7.1	COMPANY OVERVIEW	97
12.7.2	FINANCIAL OVERVIEW	98
12.7.3	PRODUCTS OFFERED	98
12.7.4	KEY DEVELOPMENTS	99
12.7.5	SWOT ANALYSIS	99
12.7.6	KEY STRATEGIES	99
12.8	ABBOTT	100
12.8.1	COMPANY OVERVIEW	100
12.8.2	FINANCIAL OVERVIEW	101
12.8.3	PRODUCTS OFFERED	101
12.8.4	KEY DEVELOPMENTS	102

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.8.5	SWOT ANALYSIS	102
12.8.6	KEY STRATEGIES	102
12.9	F. HOFFMANN-LA ROCHE LTD	103
12.9.1	COMPANY OVERVIEW	103
12.9.2	FINANCIAL OVERVIEW	104
12.9.3	PRODUCTS OFFERED	105
12.9.4	KEY DEVELOPMENTS	105
12.9.5	SWOT ANALYSIS	106
12.9.6	KEY STRATEGIES	106
12.10	YPSOMED HOLDING AG	107
12.10.1	COMPANY OVERVIEW	107
12.10.2	FINANCIAL OVERVIEW	108
12.10.3	PRODUCTS OFFERED	108
12.10.4	KEY DEVELOPMENTS	108
12.10.5	KEY STRATEGY	109
13	DATA CITATIONS	110

?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia Pacific Blood Glucose Monitoring Market Research Report Forecast to 2032

Market Report | 2024-10-12 | 111 pages | Market Research Future

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2950.00
	Enterprisewide Price	\$5250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com